Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Current Assets (2016 - 2025)

Sanofi's Current Assets history spans 6 years, with the latest figure at $45.5 billion for Q4 2024.

  • For Q4 2024, Current Assets rose 37.91% year-over-year to $45.5 billion; the TTM value through Dec 2024 reached $45.5 billion, up 37.91%, while the annual FY2024 figure was $46.1 billion, 38.94% up from the prior year.
  • Current Assets for Q4 2024 was $45.5 billion at Sanofi, up from $33.0 billion in the prior quarter.
  • Across five years, Current Assets topped out at $45.5 billion in Q4 2024 and bottomed at -$102.5 billion in Q4 2021.
  • The 3-year median for Current Assets is $33.0 billion (2023), against an average of -$8.0 billion.
  • The largest YoY upside for Current Assets was 37.91% in 2024 against a maximum downside of 37.91% in 2024.
  • A 3-year view of Current Assets shows it stood at -$102.5 billion in 2021, then soared by 132.2% to $33.0 billion in 2023, then surged by 37.91% to $45.5 billion in 2024.
  • Per Business Quant, the three most recent readings for SNY's Current Assets are $45.5 billion (Q4 2024), $33.0 billion (Q4 2023), and -$102.5 billion (Q4 2021).